<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882410</url>
  </required_header>
  <id_info>
    <org_study_id>0004_CohorteECCO2R</org_study_id>
    <nct_id>NCT04882410</nct_id>
  </id_info>
  <brief_title>Extracorporeal CO2 Removal in Acute Exacerbation of COPD Not Responding to Non-Invasive Ventilation</brief_title>
  <official_title>Extracorporeal CO2 Removal in Acute Exacerbation of COPD Not Responding to Non-Invasive Ventilation: a Single Center Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Saint-Denis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de Saint-Denis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Acute exacerbation of chronic obstructive pulmonary disease (ae-COPD) has a gold&#xD;
      standard treatment: non-invasive ventilation (NIV). However, this treatment sometime fails,&#xD;
      and an invasive mechanical ventilation (IMV) is required. The extracorporeal CO₂ removal&#xD;
      (ECCO₂R) device can be an alternative to intubation. The aim of the study is to evaluate&#xD;
      ECCO₂R efficiency and safety and enlighten ECCO₂R benefit/risk compared to IMV.&#xD;
&#xD;
      Methods: Successive ae-COPD patients for whom NIV failed were retrospectively analyzed during&#xD;
      two periods: before and after the ECCO₂R device implementation in our ICU in 2015. We&#xD;
      considered the before period as standard of care and patients were treated with IMV. The&#xD;
      ECCO₂R device was a pump-driven veno-venous system (Xenios AG).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study compare 2 strategies for COPD patients not responding to non invasive ventilation:&#xD;
      the gold standard which is mechanical ventilation and a new technique which is extracorporeal&#xD;
      CO2 removal. This technique have been implemented in februrary 2015 in our intensive care&#xD;
      unit so we choose to compare patients' outcome before and after the arriving of this device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Need for invasive mechanical ventilation despite ECCO2R technique</measure>
    <time_frame>From the begining of the ECCO2R treatment until the end of the ICU hospitalization, up to 6months</time_frame>
    <description>Rate of patients who needed invasive mechanical ventilation despite ECCO2R technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECCO2R efficiency</measure>
    <time_frame>During the treatment up to 6months</time_frame>
    <description>pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECCO2R efficiency</measure>
    <time_frame>During the treatment up to 6months</time_frame>
    <description>PaCO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects related to ECCO2R and invasive mechanical ventilation during the ICU hospitalization</measure>
    <time_frame>During the ICU hospitalization up to 6months</time_frame>
    <description>Rate of complications related to ECCO2R and invasive mechanical ventilation: hemorrhagic, thrombotic, haemodynamic, ventilator associated pneumonia, self extubation, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length of stay</measure>
    <time_frame>From the entrance in ICU until the end of hospitalization in ICU and hospital up to 6months</time_frame>
    <description>Length of stay in ICU and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 28 and day 90</measure>
    <time_frame>From the entrance in ICU until day 90</time_frame>
    <description>Mortality at day 28 and day 90</description>
  </secondary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>COPD Exacerbation Acute</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Successive ae-COPD patients for whom non-invasive ventilation failed during two periods:&#xD;
        before and after the ECCO2R device implementation in our ICU in 2015.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years old&#xD;
&#xD;
          -  no improvement or worsening of respiratory acidosis after more than one hour of non&#xD;
             invasive ventilation treatment&#xD;
&#xD;
          -  and non improvement of respiratory distress signs&#xD;
&#xD;
          -  and pH &lt; 7,35 and PaCO2 &gt; 45 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients not eligible for endotracheal intubation because of ethical limitations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 8, 2021</last_update_submitted>
  <last_update_submitted_qc>May 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier de Saint-Denis</investigator_affiliation>
    <investigator_full_name>SILVA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal carbon-dioxide removal</keyword>
  <keyword>ECCO2R</keyword>
  <keyword>Acute Exacerbation</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

